Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your diet or treatment plan.
Key Takeaways
- IBS subtypes are classified by predominant stool pattern using the Bristol Stool Form Scale — not by pain characteristics
- IBS-D accounts for roughly one-third of IBS cases and is characterised by frequent loose stools and urgency
- IBS-C involves infrequent hard stools and straining, and responds to different medications than IBS-D
- Up to 30% of patients transition between subtypes over a 12-month period, making ongoing monitoring essential
- Subtype determines first-line pharmacotherapy — prescribing the wrong medication for your subtype can worsen symptoms
Defining IBS Subtypes: The Rome IV Framework
The Rome IV classification system divides irritable bowel syndrome into four subtypes based on the predominant stool pattern on symptomatic days. Subtyping relies on the Bristol Stool Form Scale (BSFS), a validated visual tool that categorises stool into seven types ranging from hard lumps (type 1) to entirely liquid (type 7). On days when a patient experiences abnormal bowel habits, if more than 25% of stools are types 1–2 (hard), the patient is classified as IBS-C. If more than 25% are types 6–7 (loose), the classification is IBS-D.
IBS-M (mixed) is diagnosed when a patient has both more than 25% hard stools and more than 25% loose stools on symptomatic days — a pattern of alternating extremes rather than a consistent middle ground. IBS-U (unsubtyped) is used when stool abnormalities do not meet criteria for any of the other three categories. According to Dr. Eswaran, "Accurate subtyping is not merely an academic exercise — it directly determines which medications are safe and effective, and which dietary modifications to prioritise."
Population studies suggest IBS-D and IBS-C are roughly equally prevalent, each accounting for about 30–35% of IBS cases, while IBS-M represents approximately 20–25% and IBS-U the remainder. However, these proportions vary across studies depending on the population, diagnostic criteria, and recall period used.
IBS-D: Diarrhoea-Predominant IBS
IBS-D is characterised by frequent loose or watery stools, often accompanied by urgency — the sudden, compelling need to reach a bathroom. Many patients describe urgency as the most distressing symptom, more so than pain itself, because it restricts social activities, travel, and work. Stool frequency in IBS-D is typically three or more bowel movements per day, though the definition is based on consistency rather than frequency alone.
The pathophysiology of IBS-D involves accelerated colonic transit, increased intestinal secretion, altered bile acid metabolism (present in up to 30% of IBS-D patients), and visceral hypersensitivity. Post-infectious IBS, which develops after a bout of gastroenteritis, overwhelmingly presents as IBS-D and may involve low-grade mucosal inflammation and increased intestinal permeability that persist after the infection resolves.
Research from the University of Michigan shows that patients with IBS-D report lower quality-of-life scores than those with IBS-C, largely due to the unpredictability of symptoms and the fear of faecal incontinence. Dietary triggers tend to produce a faster and more dramatic response in IBS-D, making food-and-symptom tracking particularly valuable for this subtype.
IBS-C: Constipation-Predominant IBS
IBS-C presents with infrequent bowel movements (often fewer than three per week), hard or lumpy stools, excessive straining, and a sensation of incomplete evacuation. Bloating and abdominal distension are frequently reported and may be the predominant complaint, sometimes more bothersome than the constipation itself. Unlike simple functional constipation, IBS-C includes recurrent abdominal pain as a diagnostic criterion — the pain must be related to defecation or associated with a change in stool frequency or form.
The underlying mechanisms of IBS-C include delayed colonic transit, dyssynergic defecation in a subset of patients, reduced intestinal secretion, and altered rectal sensation. Visceral hypersensitivity remains a key feature, meaning that the gas and distension produced by normal fermentation are perceived as disproportionately painful. Some patients with IBS-C also have overlap with functional dyspepsia, suggesting a broader motility disorder affecting the entire gastrointestinal tract.
Dietary management of IBS-C emphasises soluble fibre supplementation (psyllium is preferred over insoluble fibre like wheat bran), adequate hydration, and regular physical activity. When dietary measures are insufficient, osmotic laxatives such as polyethylene glycol (PEG) are often used, though they treat the constipation without addressing visceral pain. Secretagogues like linaclotide address both motility and pain by acting on guanylate cyclase-C receptors in the intestinal lining.
IBS-M and IBS-U: Mixed and Unsubtyped Patterns
IBS-M can be one of the most challenging subtypes to manage because patients experience the worst of both worlds — constipation and diarrhoea in an unpredictable alternating pattern. Some patients describe cycles lasting days or weeks, while others shift within a single day. This variability makes it difficult to select a single pharmacological agent, as medications targeting diarrhoea can worsen constipation and vice versa.
The treatment approach for IBS-M typically prioritises therapies that address the dominant symptom at any given time while favouring interventions with broad-spectrum benefit. Antispasmodics, peppermint oil, neuromodulators, and gut-directed hypnotherapy are all subtype-agnostic and can be used regardless of stool pattern. Dietary management through the low-FODMAP diet is also appropriate for IBS-M, though patients may notice different trigger profiles depending on whether they are in a constipation or diarrhoea phase.
IBS-U is the least common subtype and is assigned when stool abnormalities are present but do not meet the 25% threshold for any specific pattern. In clinical practice, IBS-U is often a transitional classification — patients may eventually reclassify into another subtype as more data accumulates. For treatment purposes, IBS-U is generally managed with the same broad-spectrum approach used for IBS-M.
Subtype-Specific Treatment Strategies
Pharmacological treatment is where subtyping has the greatest practical impact. For IBS-D, first-line pharmacological options include loperamide for symptom control (though it does not reduce pain), rifaximin for bloating-predominant IBS-D, and low-dose tricyclic antidepressants such as amitriptyline which slow transit and reduce pain simultaneously. Eluxadoline (Viberzi) targets mu-opioid and kappa-opioid receptors in the gut, reducing diarrhoea and pain but is contraindicated in patients without a gallbladder.
For IBS-C, the pharmacological toolkit includes secretagogues — linaclotide (Linzess), lubiprostone (Amitiza), and plecanatide (Trulance) — which increase intestinal fluid secretion and accelerate transit. Linaclotide has the additional benefit of reducing visceral pain through a mechanism independent of its effect on motility. Prucalopride, a selective serotonin 5-HT4 receptor agonist, is another option for patients with inadequate response to secretagogues.
According to Dr. Eswaran, "I always make sure patients understand their subtype because taking the wrong medication can make things worse. An IBS-C patient who takes loperamide, for example, could end up significantly more constipated and distended. Similarly, an IBS-D patient who starts a secretagogue meant for IBS-C would likely experience worsened diarrhoea."
When Your IBS Subtype Changes
IBS subtypes are not fixed. Longitudinal studies show that approximately 25–30% of patients transition between subtypes over a 12-month period, most commonly between IBS-D and IBS-M or between IBS-C and IBS-M. These transitions can be triggered by dietary changes, medication effects, hormonal fluctuations, stress, or the natural evolution of the condition. Some patients describe a gradual shift over months, while others report a more abrupt change following a stressor or illness.
Subtype transition has important clinical implications because it may necessitate a change in pharmacological strategy. Patients who notice a sustained shift in their predominant stool pattern should discuss this with their healthcare provider. Structured symptom tracking — recording daily stool form using the Bristol Stool Scale along with associated symptoms — provides objective data that helps clinicians recognise subtype transitions early and adjust treatment accordingly.
The phenomenon of subtype fluidity also underscores the value of therapies that work across all subtypes. Dietary modification, psychological therapies, antispasmodics, and neuromodulators remain effective regardless of the predominant stool pattern, providing a stable foundation even as bowel habits fluctuate. Building a treatment plan around these cross-subtype interventions, supplemented with subtype-specific medications as needed, offers the most resilient long-term strategy.
Sources
- 1. Drossman DA, Hasler WL. Rome IV — Functional Gastrointestinal Disorders: Disorders of Gut-Brain Interaction (2016).
- 2. Lacy BE, Pimentel M, Brenner DM et al.. ACG Clinical Guideline: Management of Irritable Bowel Syndrome (2021).
- 3. Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome: a clinical review (2020).
- 4. Camilleri M. Bile acid diarrhea: prevalence, pathogenesis, and therapy (2015).
Frequently Asked Questions
How do I know which IBS subtype I have?
Your IBS subtype is determined by the predominant stool consistency on days when you experience abnormal bowel habits, using the Bristol Stool Form Scale. If more than 25% of abnormal stools are loose (types 6-7), you have IBS-D. If more than 25% are hard (types 1-2), you have IBS-C. If both thresholds are met, you have IBS-M. Your doctor can help classify your subtype based on a symptom diary.
Can my IBS subtype change over time?
Yes. Studies show that approximately 25-30% of IBS patients transition between subtypes within a 12-month period. The most common transitions are between IBS-D and IBS-M or between IBS-C and IBS-M. This is a normal part of the condition, but it may require adjustments to your treatment plan.
Is one IBS subtype worse than another?
Quality-of-life studies show that IBS-D patients tend to report the greatest impact due to urgency and fear of incontinence. However, severity varies enormously between individuals regardless of subtype. A patient with severe IBS-C can be more affected than someone with mild IBS-D. Severity depends on symptom intensity, psychological impact, and how well symptoms respond to treatment.
Does the low-FODMAP diet work for all IBS subtypes?
Yes. The low-FODMAP diet has been shown to improve symptoms across all IBS subtypes, though the mechanism differs. In IBS-D, reducing FODMAPs decreases osmotic water draw and rapid fermentation. In IBS-C, it primarily reduces bloating and gas. Response rates are generally similar across subtypes, making it a versatile first-line dietary intervention.
Why is IBS subtyping important for medication choice?
Medications for IBS are subtype-specific. Secretagogues like linaclotide increase intestinal fluid and are designed for IBS-C — they would worsen IBS-D. Conversely, loperamide and bile acid sequestrants slow transit and are used for IBS-D — they would worsen IBS-C. Taking the wrong medication for your subtype can significantly aggravate symptoms.
What is post-infectious IBS and which subtype does it cause?
Post-infectious IBS (PI-IBS) develops after an acute episode of gastroenteritis. It accounts for about 10% of all IBS cases and overwhelmingly presents as IBS-D, likely due to persistent low-grade inflammation, increased intestinal permeability, and altered serotonin signalling following the initial infection. PI-IBS generally has a better prognosis than non-PI-IBS.
Can I have IBS-D and still experience constipation sometimes?
Yes. IBS subtyping is based on the predominant pattern, not an absolute one. IBS-D patients may occasionally experience constipation, especially when travelling, changing routines, or taking certain medications. If constipation becomes frequent and accounts for more than 25% of abnormal stools, your classification may shift to IBS-M.
Related Tools
Related Features in Symbiota
Related Glossary Terms
Related Articles
Ready to Take Control of Your Gut Health?
Start your evidence-based gut health journey today. Free to download, no credit card required.
Download on App Store